One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The macro of the moment is protein, and it’s not much of a competition. Everyone is paying attention to their protein intake ...

"Their effects on vaginal health are an important consideration that is often overlooked," gynecologist Melanie Bone told ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

About 154 million non-elderly Americans rely on employer-sponsored coverage, and the 26th annual survey of more than 2,100 ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest ...